Skip to main content
Skip to footer

  • WHITE PAPER

Pharma Firms Switch Gears from Response to Transformation

Debashis Ghosh

President of Life Sciences, Healthcare, Public Services and Energy Business Group, TCS

Sanjeev Sachdeva

CTO and Global Head Advisory Services – Life Sciences, TCS

You have these already downloaded

We have sent you a copy of the report to your email again.

The crisis has triggered the need for meaningful partnerships within pharma to speed up R&D and become future ready  

Pharmaceuticals firms are facing disruptions across the value chain – with existing clinical trials, manufacturing operations, supply chain, and commercial operations - that may have a profound and lasting impact on some of their business models and operations going forward.

 

 

Related reading

How the World Entered the Business of Human Microbiome

White Paper | 13 Nov 2022

Modernizing Pharma Regulatory Knowledge Management  

White Paper | 27 Oct 2022

Blockchain in pharma: Promoting a sustainable ecosystem

White Paper | 24 Oct 2022

Next-gen pharmacovigilance ― Key digital transformation drivers

Blog | 27 Jul 2022

Transformation starts here

Integrated ecosystems are key to better patient outcomes.

Talk to our experts

Find out more